207_Combined course Presentations
Etanidazole
RTOG 85-27, 504 H&N patients
100
100
80
80
60
60
RT + Eta
38% 39%
RT + Eta
40
40
27% 22%
RT
Crude survival (%)
RT
20
20
n.s.
n.s.
Loco-regional control (%)
0
0 1 2 3 4 5 Years after treatment 0
1 2 3 4 5 Years after treatment
Lee et al. 1995
Made with FlippingBook